These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33800195)

  • 1. Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy.
    Ishitsuka Y; Hanaoka Y; Tanemura A; Fujimoto M
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sun protection for preventing basal cell and squamous cell skin cancers.
    Sánchez G; Nova J; Rodriguez-Hernandez AE; Medina RD; Solorzano-Restrepo C; Gonzalez J; Olmos M; Godfrey K; Arevalo-Rodriguez I
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011161. PubMed ID: 27455163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
    Fania L; Didona D; Di Pietro FR; Verkhovskaia S; Morese R; Paolino G; Donati M; Ricci F; Coco V; Ricci F; Candi E; Abeni D; Dellambra E
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33572373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.
    Venables ZC; Nijsten T; Wong KF; Autier P; Broggio J; Deas A; Harwood CA; Hollestein LM; Langan SM; Morgan E; Proby CM; Rashbass J; Leigh IM
    Br J Dermatol; 2019 Sep; 181(3):474-482. PubMed ID: 30864158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Squamous Cell Carcinoma: The Frontier of Cancer Immunoprevention.
    Chang MS; Azin M; Demehri S
    Annu Rev Pathol; 2022 Jan; 17():101-119. PubMed ID: 35073167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma.
    Piipponen M; Riihilä P; Nissinen L; Kähäri VM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.
    Boutros A; Cecchi F; Tanda ET; Croce E; Gili R; Arecco L; Spagnolo F; Queirolo P
    Front Oncol; 2021; 11():733917. PubMed ID: 34513710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global status of research on cutaneous squamous cell carcinoma and its programmed cell death: Bibliometric and visual analysis from 2012 to middle 2022.
    Zhang Y; Guo Z; Wang H; Li B
    Front Oncol; 2023; 13():1099382. PubMed ID: 37114133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.
    Siegel JD; Bhatia A; Ko CJ; Christensen SR
    JAAD Case Rep; 2021 Dec; 18():23-25. PubMed ID: 34778502
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1.
    Wang X; Li Z; Sun Y
    Skin Res Technol; 2023 Jan; 29(1):e13254. PubMed ID: 36478592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the squamous cell carcinoma immune microenvironment.
    Saeidi V; Doudican N; Carucci JA
    Front Immunol; 2023; 14():1084873. PubMed ID: 36793738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside.
    Goodman DT
    JPRAS Open; 2022 Sep; 33():155-160. PubMed ID: 36046255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.
    Corchado-Cobos R; García-Sancha N; González-Sarmiento R; Pérez-Losada J; Cañueto J
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report:
    Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
    Front Immunol; 2021; 12():752563. PubMed ID: 35003064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of advanced cutaneous squamous cell carcinoma.
    de Jong E; Lammerts MUPA; Genders RE; Bouwes Bavinck JN
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1(Suppl 1):6-10. PubMed ID: 34855246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
    Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
    J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.